Skip to main content
. 2006 Jul 18;92(12):1768–1772. doi: 10.1136/hrt.2006.079707

Table 1 Baseline characteristics in the levosimendan‐treated and placebo‐treated groups.

Levosimendan (n = 17) Placebo (n = 8) p Value*
Age (years) 67 (6) 70 (8) NS
Male:female 16:1 7:1 NS
NYHA class III/IV
7/10 4/4 NS
BSA (m2) 1.95 (0.18) 1.97 (0.11) NS
Cardiomyopathy NS
 Ischaemic/dilated 14/3 7/1
Heart rate (beats/min) 74 (9) 73 (8) NS
Systolic blood pressure (mm Hg) 117 (14) 110 (15) NS
Diastolic blood pressure (mm Hg) 73 (8) 71 (8) NS
LV end‐diastolic diameter index (mm/m2) 36 (4) 37 (4) NS
LV end‐systolic diameter index (mm/m2) 31 (5) 31 (4) NS
LV ejection fraction (%) 22 (4) 23 (4) NS
LV end‐diastolic volume index (ml/m2) 133 (25) 144 (29) NS
LV end‐systolic volume index (ml/m2) 95 (28) 98 (25) NS
LV end‐systolic wall stress (g/cm2) 859 (129) 807 (107) NS
Serum creatinine (μmol/l) 115 (27) 124 (18) NS
Drugs NS
 ACE inhibitors 17 8
 Diuretics 17 8
 β‐blockers 14 6
 Aldosterone antagonists 9 4
 Amiodarone 7 3

Values are mean (SD).

ACE, angiotensin‐converting enzyme; BSA, body surface area; LV, left ventricular; NS, not significant; NYHA, New York Heart Association.

*Student's t test, Mann–Whitney U test or χ2 test, as appropriate.